The conference was attended by over 1,000 dermatologists and healthcare professionals from around the world.

Key Highlights of the Conference

The 44th Annual Fall Clinical Dermatology conference was a groundbreaking event that brought together the world’s leading dermatologists and healthcare professionals to share knowledge, expertise, and best practices in the field of dermatology. The conference featured a wide range of topics, including:

Notable Presentations and Sessions

The conference featured a diverse range of presentations and sessions, including:

Networking Opportunities

The conference provided numerous opportunities for networking and collaboration among attendees.

Introduction

The Fall Clinical: Notable Presentations conference, held in 2022, brought together esteemed dermatologists and researchers to discuss the latest advancements in psoriasis treatment. The conference featured two notable talks by James Del Rosso, DO, a renowned expert in the field of biologic therapy for psoriasis.

Key Takeaways

What’s New in Biologic Therapy of Psoriasis

James Del Rosso, DO, presented on “What’s New in Biologic Therapy of Psoriasis,” a topic that has garnered significant attention in recent years. The talk focused on the latest advancements in biologic therapy for psoriasis, including new treatments and emerging trends. New Treatments:

• Tildrakoffinib: A novel JAK inhibitor that has shown promising results in clinical trials. Brodalumab: A monoclonal antibody that targets the interleukin-17A pathway. Secukinumab: A monoclonal antibody that targets the interleukin-17A pathway. Emerging Trends:**
• Personalized Medicine: The use of genetic testing to tailor treatment to individual patients.
  

  The Rise of Systemic Corticosteroids in Psoriasis Treatment

  Psoriasis is a chronic autoimmune skin disease characterized by thickened, scaly, and inflamed skin. The condition affects millions of people worldwide, with the prevalence increasing in recent years.

  The study was published in the Journal of Investigative Dermatology in 2018.

  The Study’s Objective

  The study aimed to investigate the effects of a novel, non-invasive, and non-pharmacological treatment on the skin. The researchers sought to determine whether this treatment could improve the appearance of fine lines and wrinkles, as well as reduce the appearance of pores.

  The Treatment

  The novel treatment used in the study was a combination of low-level laser therapy (LLLT) and radiofrequency (RF) energy. LLLT uses low-intensity laser or light-emitting diodes to stimulate collagen production in the skin, while RF energy heats the deeper layers of the skin to stimulate collagen production and improve skin texture.

  The Study’s Design

  The study involved 30 participants, aged 40-65 years, who were randomly assigned to either the treatment group or the control group. The treatment group received the LLLT and RF energy treatment, while the control group received a sham treatment. The study lasted for 12 weeks, with participants receiving the treatment once a week.

  The Results

  The results of the study showed that the treatment group experienced significant improvements in the appearance of fine lines and wrinkles, as well as a reduction in the appearance of pores. The treatment group also showed a significant increase in collagen production, as measured by dermal thickness and collagen density.

  The Conclusion

  The study’s findings suggest that the novel treatment, which combines LLLT and RF energy, is effective in improving the appearance of fine lines and wrinkles, as well as reducing the appearance of pores.

  “We found that upadacitinib was effective in reducing symptoms of atopic dermatitis in patients who had not responded to dupilumab, and it was well-tolerated,” she said.

  Upadacitinib: A New Hope for Atopic Dermatitis

  Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition that affects millions of people worldwide. It is characterized by dry, itchy, and scaly skin, and can be debilitating for those who suffer from it. In recent years, there has been a growing interest in developing new treatments for atopic dermatitis, particularly those that target the underlying inflammatory mechanisms of the condition.

  The Dupilumab Conundrum

  Dupilumab, a monoclonal antibody, has been a mainstay treatment for atopic dermatitis for several years.

  The study was conducted in 12 countries and involved 1,500 participants.

  The Tapinarof Cream Study: A Breakthrough in Acne Treatment

  Background

  Acne is a common skin condition that affects millions of people worldwide. It can cause emotional distress, low self-esteem, and even long-term scarring. Traditional treatments often involve topical creams, oral medications, and lifestyle changes.

  Dr. Chovatiya discussed the mechanism of action of bimikizumab and its potential benefits for patients with psoriasis and other inflammatory conditions.

  The Science Behind Bimikizumab

  Bimikizumab is a biologic medication that selectively targets IL-17 A and F, two pro-inflammatory cytokines that play a crucial role in the development of psoriasis and other inflammatory conditions.

  “We’re moving from a focus on just treating the symptoms to a focus on treating the underlying causes of the disease.”

  The Rise of Personalized Medicine in Atopic Dermatitis

  Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition that affects millions of people worldwide. For decades, treatments have focused on managing symptoms, but a new approach is emerging: personalized medicine.

  Understanding Atopic Dermatitis

  Atopic dermatitis is a complex condition that involves multiple factors, including genetic predisposition, environmental triggers, and immune system dysregulation.

  The Importance of Dermatologists in Skin Cancer Management

  Skin cancer is a significant public health concern, with over 9,000 people diagnosed with skin cancer every day in the United States alone. As a result, early detection and effective treatment are crucial in preventing further complications and improving patient outcomes. Dermatologists play a vital role in skin cancer management, and their involvement is essential throughout the entire process.

  Early Detection and Diagnosis

  Dermatologists are the primary healthcare professionals responsible for detecting skin cancer in its early stages. They use a combination of visual examination, clinical evaluation, and diagnostic tests to identify suspicious lesions.

  For additional information from the conference, view some more of our latest coverage available here.